title: When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis.
authors.forename: F H M
authors.initials: FH
authors.lastname: Prince
authors.forename: M
authors.initials: M
authors.lastname: Twilt
authors.forename: S C M
authors.initials: SC
authors.lastname: Simon
authors.forename: M A J
authors.initials: MA
authors.lastname: van Rossum
authors.forename: W
authors.initials: W
authors.lastname: Armbrust
authors.forename: E P A H
authors.initials: EP
authors.lastname: Hoppenreijs
authors.forename: S
authors.initials: S
authors.lastname: Kamphuis
authors.forename: M
authors.initials: M
authors.lastname: van Santen-Hoeufft
authors.forename: Y
authors.initials: Y
authors.lastname: Koopman-Keemink
authors.forename: N M
authors.initials: NM
authors.lastname: Wulffraat
authors.forename: R
authors.initials: R
authors.lastname: ten Cate
authors.forename: L W A
authors.initials: LW
authors.lastname: van Suijlekom-Smit
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept